Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BD and Ypsomed Develop 5.5mL Syringe Variant in Expansion of Partnership | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

BD and Ypsomed Develop 5.5mL Syringe Variant in Expansion of Partnership

The new version of the BD Neopak XtraFlow glass prefillable syringe is designed to be fully compatible with Ypsomed’s YpsoMate 5.5 autoinjector platform.

Author Image

By: Patrick Lavery

Content Marketing Editor

BD (Becton, Dickinson and Company) and Ypsomed are strengthening an existing collaboration with a new version of a glass prefillable syringe.

The 5.5mL version of the BD Neopak XtraFlow syringe is fully compatible with Ypsomed’s YpsoMate 5.5 autoinjector platform. Accordingly, it expands options for pharmaceutical companies, and patients requiring large-volume, subcutaneous self-injections.

YpsoMate was first introduced in 2022. Among its features are an ergonomic design, two-step activation, and clear feedback. The last of these, Ypsomed says, supports patient confidence and ease of use.

Syringe Adjusts to Biologics Needs

By definition, large-volume subcutaneous biologics injections are greater than 1 mL. Increasingly, they are common in treatments for oncology, autoimmune and rare diseases, and metabolic disorders.

In support of this, the new BD syringe has a shorter (8mm) needle and thinner wall cannulas. This in turn facilitates delivery of higher volume and viscosity medicines.

Ideally, BD and Ypsomed said, such enhancements enable improved injection time and optimized flow. These can be common challenges in large-volume biologics.

BD, Ypsomed Leaders React

In response to this latest collaboration, both companies touted the benefits of the new syringe.

“This next-generation syringe is a direct response to the growing demand for patient-friendly solutions in the high-dose biologics space,” said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. “By combining BD’s expertise in drug delivery with Ypsomed’s leadership in autoinjector platforms, we are helping to simplify self-injection for patients managing complex conditions.”

“Ypsomed and BD, in close collaboration with our pharmaceutical partners, are expanding the subcutaneous delivery design space to accommodate high-dose therapies, both volume and viscosity,” said Ulrike Bauer, Ypsomed Chief Business Officer. “These partnerships are critical as we jointly drive the future of high-dose biopharmaceutical delivery.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics